Cargando…
COVID-19 vaccine trials: The use of active controls and non-inferiority studies
BACKGROUND: Recently emerging results from a few placebo-controlled randomized trials of COVID-19 vaccines revealed estimates of 62%–95% relative reductions in risk of virologically confirmed symptomatic COVID-19 disease, over approximately 2-month average follow-up period. Additional safe and effec...
Autores principales: | Fleming, Thomas R, Krause, Philip R, Nason, Martha, Longini, Ira M, Henao-Restrepo, Ana-Maria M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172418/ https://www.ncbi.nlm.nih.gov/pubmed/33535811 http://dx.doi.org/10.1177/1740774520988244 |
Ejemplares similares
-
COVID-19 vaccine trials should seek worthwhile efficacy
por: Krause, Philip, et al.
Publicado: (2020) -
Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential
por: Krause, Philip R, et al.
Publicado: (2020) -
A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats
por: Longini, Ira M, et al.
Publicado: (2022) -
Considerations in boosting COVID-19 vaccine immune responses
por: Krause, Philip R, et al.
Publicado: (2021) -
Booster vaccines for COVID-19 vaccine breakthrough cases? – Authors' reply
por: Krause, Philip R, et al.
Publicado: (2022)